This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Next Step for Amag's Board: Fire CEO, Sell the Company.

Stocks in this article: AMAG ALTH AMGN JNJ

LEXINGTON, Mass. ( TheStreet) -- Amag Pharmaceuticals (AMAG) shareholders did the right thing Friday by rejecting the proposed merger with Allos Therapeutics (ALTH).

The next step should be just as clear: Amag's board needs to wake up, fire CEO Brian Pereira begin a formal auction process to find an appropriate buyer for the company's only valuable asset, the therapeutic iron compound Feraheme.

By killing the Allos deal, Amag shareholders are sending a very clear message to the board that they have no confidence in Pereira's leadership. Pereira had his chance to turn Amag around but he failed. It's time to put someone else in charge.

"We recognize the need to augment our leadership to align the skill sets of the management team with the needs of a multi-product specialty pharmaceutical company and have embarked on this effort," said Amag spokeswoman Amy Sullivan in response to my question about whether Pereira should resign.

Does "augmenting our leadership" mean sending Pereira packing? Sullivan didn't say, but let's hope so. Adding another layer of middle managers at Amag isn't going to solve the problem.

On a conference call following the vote, Pereira says he's heard from shareholders who believe in his strategy of adding new drugs to leverage the commercial infrastructure built to market Feraheme. Yet if that's true, why was Pereira's first choice to bolster Amag's portfolio -- the floppish cancer drug Folotyn -- so universally panned?

Sure, it would be great if Amag could license or acquire additional drugs to diversify beyond Feraheme, but Pereira isn't going to be the guy to accomplish that goal. He botched the Feraheme launch then delivered the Allos deal dead on arrival. With Amag's credibility even more tarnished now, Pereira isn't likely to buy or license other new drugs.

Feraheme can be a moneymaking drug in the hands of a company with an existing commercial infrastructure. Amag's board needs to reach out to Amgen (AMGN), Johnson & Johnson (JNJ), Takeda and others. Feraheme's value to a potential buyer is likely to increase if results are positive from an ongoing phase III study in iron deficiency anemia.

The road ahead for Amag's board is simple: Fire Pereira. Sell the company.

Shareholders have suffered enough. It's time to do something right by them.

--Written by Adam Feuerstein in Boston.



>To contact the writer of this article, click here: Adam Feuerstein.

>To follow the writer on Twitter, go to http://twitter.com/adamfeuerstein.

>To submit a news tip, send an email to: tips@thestreet.com.

Follow TheStreet on Twitter and become a fan on Facebook.

Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 18,030.21 +6.04 0.03%
S&P 500 2,081.88 -0.29 -0.01%
NASDAQ 4,773.4720 +8.0480 0.17%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs